Now Approved: U.S. FDA approves product to reduce the incidence of catheter-related bloodstream infections (CRBSIs) under special pathway for patients receiving hemodialysis.

CORMEDIX INC. ANNOUNCES FDA DECISION THAT ADVISORY COMMITTEE MEETING FOR NEW DRUG APPLICATION FOR DEFENCATH IS NOT NEEDED

Here you can find corporate releases on topics related to governance, investments and important announcements.

CORMEDIX INC. ANNOUNCES FDA APPROVAL OF DEFENCATH® TO REDUCE THE INCIDENCE OF CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT HEMODIALYSIS PATIENTS

Read more
2023-11-15

CORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2023-11-14

CORMEDIX INC. TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 14, 2023

Read more
2023-11-06

CORMEDIX INC. TO PRESENT AT THE CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE

Read more
2023-09-26

CORMEDIX INC. TO PRESENT AT THE H.C. WAINWRIGHT ANNUAL GLOBAL INVESTMENT CONFERENCE

Read more
2023-09-06

CORMEDIX INC. ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD PRODUCT DEFENCATH

Read more
2023-08-30

CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2023-08-08

CORMEDIX INC. TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 8, 2023

Read more
2023-07-27

CORMEDIX INC. ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

Read more
2023-06-28

CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

Read more

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE OF RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH

Read more
2023-06-21

CORMEDIX INC. ANNOUNCES STRATEGIC INITIATIVE WITH BOSTON MEDICAL CENTER TO REDUCE HEALTH DISPARITIES IN PATIENTS AT RISK FOR BLOODSTREAM INFECTIONS

Read more
2023-06-15

CORMEDIX INC. TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE

Read more
2023-05-30

CORMEDIX INC. ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH

Read more
2023-05-16

CORMEDIX INC. TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 15, 2023

Read more
2023-05-08

CORMEDIX INC. TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

Read more
2023-05-03

CORMEDIX INC. ANNOUNCES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION COVERING LEAD PRODUCT DEFENCATH

Read more
2023-05-01

CORMEDIX INC. ANNOUNCES REGULATORY, MANUFACTURING AND REIMBURSEMENT UPDATES

Read more
2023-04-26

CORMEDIX INC. ANNOUNCES APPOINTMENT OF ROBERT A. STEWART TO ITS BOARD OF DIRECTORS

Read more
2023-04-17

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2023-03-30

CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES

Read more
2023-03-02

CORMEDIX INC. ANNOUNCES PROMOTIONS IN COMMERCIAL AND TECH OPS

Read more
2023-01-18

CORMEDIX INC. ANNOUNCES PRESENTATION AT CONFERENCE SHOWING MORTALITY RISK AND COMPLICATIONS IN PATIENTS EXPERIENCING CATHETER RELATED BLOOD STREAM INFECTIONS

Read more
2022-12-06

CORMEDIX INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2022-11-10

CORMEDIX INC. TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 10

Read more
2022-11-02

CORMEDIX INC. ANNOUNCES ABSTRACT PRESENTATION AT UPCOMING AMERICAN SOCIETY OF NEPHROLOGY CONFERENCE

Read more
2022-10-20

CORMEDIX INC. ANNOUNCES CMS REVISION TO NTAP REIMBURSEMENT OF DEFENCATH

Read more
2022-09-07

CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update

Read more
2022-08-11

CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES

Read more
2022-08-08

CORMEDIX INC. TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 11

Read more
2022-08-01

CorMedix to Participate at the JMP Securities Life Sciences Conference

Read more
2022-06-08

CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Read more
2022-05-12

CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES

Read more

CORMEDIX INC. TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12

Read more
2022-05-03

CORMEDIX INC. ANNOUNCES SCIENTIFIC ADVISORY BOARD TO SUPPORT COMMERCIALIZATION and pipeline development

Read more
2022-04-07

CORMEDIX INC. to Present at the 21st Annual Needham Virtual Healthcare Conference

Read more
2022-04-04

CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2022-03-29

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH

Read more
2022-03-28

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29

Read more
2022-03-22

CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Read more
2022-03-17

CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH

Read more
2022-02-28

CORMEDIX TO PARTICIPATE IN UPCOMING JANUARY CONFERENCES

Read more
2022-01-04

CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2021-11-09

CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9

Read more
2021-11-02

CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING CONFERENCES SHOWING PATIENT OUTCOMES AND ECONOMIC BURDEN OF CRBSI

Read more
2021-10-20

CORMEDIX INC. ANNOUNCES EXECUTIVE LEADERSHIP CHANGES

Read more
2021-10-04

CORMEDIX INC. ANNOUNCES REGULATORY UPDATE

Read more
2021-09-07

CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2021-08-12

CorMedix Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12

Read more
2021-07-28

CorMedix Inc. Completes Sale of $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program

Read more
2021-06-10

CorMedix Inc. to Participate in Fireside Chat at the JMP Securities Life Sciences Conference

Read more
2021-06-09

CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference

Read more
2021-05-27

CorMedix Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

Read more
2021-05-13

CorMedix Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13

Read more
2021-05-05

CORMEDIX INC. TO PARTICIPATE AT THE 7th ANNUAL TRUIST SECURITIES LIFE SCIENCES SUMMIT

Read more
2021-04-28

CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA

Read more
2021-04-14

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2021-03-30

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30

Read more
2021-03-23

CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program

Read more
2021-03-15

CorMedix Inc. to Host Regulatory Update Conference Call

Read more
2021-03-08

CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION

Read more
2021-03-01

CORMEDIX INC. TO BEGIN TRADING ON THE NASDAQ STOCK EXCHANGE

Read more
2021-01-21

CORMEDIX INC. ANNOUNCES FDA DECISION THAT ADVISORY COMMITTEE MEETING FOR NEW DRUG APPLICATION FOR DEFENCATH IS NOT NEEDED

Read more
2020-11-18

CORMEDIX INC. REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2020-11-05

CorMedix Appoints Greg Duncan to its Board of Directors

Read more
2020-11-02

CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5

Read more
2020-10-29

CorMedix to Participate in BIO Investor Forum Digital

Read more
2020-10-08

Cormedix Appoints Paulo Costa to its Board of Directors

Read more
2020-09-17

CorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Read more
2020-09-09

CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR DEFENCATH

Read more
2020-08-31

CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2020-08-10

CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10

Read more
2020-08-04

CorMedix Announces Pricing of $20M Public Offering of Common Stock

Read more
2020-07-28

CorMedix Announces Proposed Public Offering of Common Stock

Read more
2020-07-27

CORMEDIX INC. REPORTS SUBMISSION OF DEFENCATH™ NEW DRUG APPLICATION

Read more
2020-07-08

CORMEDIX INC. REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2020-05-11

CORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

Read more

CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®

Read more
2020-05-06

CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program

Read more
2020-04-22

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2020-03-17

CorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16

Read more
2020-03-06

CORMEDIX APPROVED TO SELL $5.5 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM

Read more
2020-02-03

CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application

Read more

CORMEDIX INC. REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2019-11-14

CorMedix Inc. Announces a Change to its Senior Leadership

Read more
2019-11-06

CORMEDIX COMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA

Read more
2019-10-21

CORMEDIX INC. ANNOUNCES EXERCISES OF OUTSTANDING WARRANTS

Read more
2019-09-30

CORMEDIX INC. ANNOUNCES EXCHANGE AGREEMENT WITH ITS LARGEST INVESTOR

Read more
2019-08-15

CORMEDIX PRESENTS AT FDA PUBLIC MEETING ON THE LIMITED POPULATION PATHWAY FOR ANTIBACTERIAL AND ANTIFUNGAL DRUGS

Read more
2019-07-17

CORMEDIX RECEIVES ENCOURAGING FDA FEEDBACK ON NEUTROLIN® LOCK-IT-100 DATA

Read more
2019-07-09

CORMEDIX ANNOUNCES PUBLICATION OF TAUROLIDINE PRE-CLINICAL ONCOLOGY DATA IN “INVESTIGATIONAL NEW DRUGS” JOURNAL

Read more
2019-07-08

CorMedix Inc. Set to Join the Russell 2000® Index

Read more
2019-06-26

CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10

Read more
2019-06-10

CORMEDIX INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2019-05-14

CORMEDIX ANNOUNCES PRESENTATION OF LOCK-IT-100 STUDY RESULTS AT NATIONAL KIDNEY FOUNDATION SPRING 2019 MEETING

Read more
2019-05-10

CORMEDIX ANNOUNCES ONLINE PRE-CLINICAL ABSTRACT AT THE UPCOMING ANNUAL MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Read more
2019-04-22

CORMEDIX COMPLETES SALE OF $5.4 MILLION OF NOL TAX BENEFITS THROUGH NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM

Read more
2019-04-17

CORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN LISTING REQUIREMENTS

Read more
2019-04-11

CORMEDIX CONFIRMS PREVIOUSLY ANNOUNCED ONE-FOR-FIVE REVERSE STOCK SPLIT

Read more
2019-03-25

CORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL

Read more
2019-03-21

CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, ANNOUNCES REVERSE STOCK SPLIT AND PROVIDES BUSINESS UPDATE

Read more
2019-03-14

CORMEDIX INC. APPOINTS ALAN W. DUNTON, M.D. TO BOARD OF DIRECTORS

Read more
2019-03-04

CORMEDIX INC. ANNOUNCES FDA MEETING UPDATE

Read more
2019-02-14

CORMEDIX INC. ANNOUNCES TOPLINE ANALYSIS OF THE FULL DATA SET OF PHASE 3 LOCK-IT-100 STUDY REINFORCES THE INTERIM RESULTS

Read more
2019-01-30

CORMEDIX INC. ANNOUNCES HIGHLY STATISTICALLY SIGNIFICANT TOPLINE RESULTS FOR NEUTROLIN® FROM THE INTERIM ANALYSIS OF THE PHASE 3 LOCK-IT-100 STUDY

Read more
2019-01-17

CORMEDIX INC. ANNOUNCES RESIGNATION OF MEMBER OF ITS BOARD OF DIRECTORS

Read more

CORMEDIX ANNOUNCES CLOSING OF $7.5 MILLION SENIOR SECURED CONVERTIBLE DEBT FINANCING

Read more
2019-01-07

CORMEDIX RECEIVES APPROVAL TO SELL $5.4 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM

Read more
2018-12-10

CORMEDIX INC. REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call today at 4:30 p.m. Eastern Time

Read more
2018-11-14

CORMEDIX INC. CLARIFIES THAT NO NEW SHARES ARE BEING ISSUED IN CONNECTION WITH ITS RECENTLY FILED FORM S-3 REGISTRATION STATEMENT

Read more
2018-10-18

CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Read more
2018-08-31

CORMEDIX INC. TO PRESENT AT THE 20TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE

Read more
2018-08-30

CORMEDIX INC. REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2018-08-14

CORMEDIX INC. ANNOUNCES POSITIVE RESULTS OF ITS NEUTROLIN® PHASE 3 LOCK-IT-100 STUDY BASED ON RECOMMENDATION BY INDEPENDENT DATA SAFETY MONITORING BOARD

Read more
2018-07-25

CORMEDIX INC. COMPLETES REVIEW AND SOURCE VERIFICATION OF PHASE 3 LOCK-IT 100 DATA FOR NEUTROLIN®

Read more
2018-06-20

CORMEDIX INC. RECEIVES A CONTINUED LISTING STANDARD NOTICE FROM THE NYSE AMERICAN

Read more
2018-06-19

CORMEDIX INC. REPORTS PROGRESS ON LOCK-IT 100 DATA REVIEW AND APPOINTS PAUL CHEW AS CONSULTANT ADVISOR CMO

Read more
2018-05-29

CORMEDIX INC. REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2018-05-15

CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15

Read more
2018-05-09

CorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management

Read more
2018-04-27

CORMEDIX INC. REPORTS Fourth QUARTER and Full-year 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Read more
2018-03-19

CorMedix Inc. Provides Update on its Financing Plans in Connection with its Ongoing LOCK-IT 100 Clinical Study

Read more
2018-02-27

CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

Read more
2018-02-26

CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin® for Interim Efficacy Analysis

Read more
2018-02-20